“What worries me is how many people have missed the chance for personalized medicine, like targeted therapies, and just receive chemotherapy by default. It could be shortening their lives.”
NeoGenomics is your single destination for all stages of lung cancer
Immuno-Oncology (I-O), also known as cancer immunotherapy, is a type of cancer treatment that boosts one’s own immune system to fight cancer. Often, if cancer cells have high levels of PD-L1, a predictive biomarker detectable by immunohistochemistry, patients may benefit from immunotherapy.
NeoGenomics was the first oncology diagnostic laboratory to run PD-L1 testing with the launch of pembrolizumab immunotherapy and remains a key provider of immuno-oncology testing, running over 70,000 PD-L1 tests annually.
Please download NeoGenomics’ immuno-oncology brochure to learn more about the suite of companion and complementary PD-L1 testing offered.
Tumor profiling has become fundamental to inform cancer diagnosis and prognosis but also to drive therapeutic decisions in clinical practice. Tailored to fit the many clinical needs of patients and oncology providers, NeoGenomics offers a variety of comprehensive and targeted approaches to drive precision medicine decisions in patients with lung cancer. Our multi-modal panels provide clear results on tumor-specific alterations, immune-oncology expression and access to open clinical trials. Please learn more about our tumor profiles.
NeoTYPE® Lung Tumor Profile is a targeted molecular profile designed to detect genomic alterations in clinically significant driver genes based on multi-method detection techniques centered primarily on next-generation sequencing, but also including selected immunohistochemical and FISH assays.
The Lung NGS Fusion Profile is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes ALK, NTRK1, NTRK2, NTRK3, RET and ROS1 with known and novel fusion partners.
NeoTYPE® Discovery Profile analyzes 336 biomarkers through a combination of next-generation sequencing (NGS), FISH, and immunohistochemistry, as listed below.
Biomarker profiling is crucial for patients with lung cancer and key to initiate precision medicine decisions. Currently there are over 15 biomarker-driven targeted therapies for NSCLC and several other targeted-therapies for both NCSLC and small cell lung cancer. Additionally, immuno-oncology treatments are available, often driven by PD-L1 status.
Comprehensive or broad panel testing may not be an option for all patients. Please visit our test menu to learn more about our single-gene assays such as EGFR, ROS1, ALK, NTRK, BRAF and many more.
Liquid biopsy in cancer testing is a unique approach to genomic profiling. Although tissue-based assays are the gold standard to tumor profiling, quality and availability of tumor tissue often times poses a challenge to implement of precision medicine. Liquid biopsies are easily accessible through a minimally invasive procedure to help inform treatment strategies, monitor disease progression or evaluate therapeutic effectiveness.
InVisionFirst®-Lung is a focused and actionable NGS-based liquid biopsy assay covering the guideline-recommended genomic drivers with available targeted therapies. Clinical validation studies have shown a 98% concordance to matched tumor tissue.
Learn about Neo’s own Rachael Malmberg’s lung cancer journey
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients